HUMANIGEN, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0002 USD | 0.00% |
|
+19,900.00% | -83.33% |
| Apr. 12 | Combined Liquidation Plan and Disclosure Statement Filed by Humanigen, Inc. | CI |
| Mar. 08 | Final DIP Financing Approved for Humanigen, Inc. | CI |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 6.016 | 76.91 | 55.34 | 903.3 | 237.4 | 14.29 |
| Enterprise Value (EV) 1 | 24.65 | 79.59 | 61.69 | 835.6 | 192.4 | 4.135 |
| P/E ratio | -0.27 x | -5.53 x | -5.29 x | -7.22 x | -0.92 x | -0.15 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | 2,895,156,699 x | 66,037,226 x | 5,684,016 x |
| EV / Revenue | - | - | - | 2,678,050,929 x | 53,517,059 x | 1,644,636 x |
| EV / EBITDA | -1.3 x | -7.04 x | -6.91 x | - | - | - |
| EV / FCF | -2.75 x | -27.1 x | -37.5 x | -20.1 x | -2.05 x | -0.08 x |
| FCF Yield | -36.4% | -3.7% | -2.66% | -4.98% | -48.7% | -1,239% |
| Price to Book | -0.25 x | -9.48 x | -3.88 x | 19.8 x | -10.1 x | -0.31 x |
| Nbr of stocks (in thousands) | 2,989 | 21,975 | 22,704 | 51,617 | 63,818 | 119,080 |
| Reference price 2 | 2.012 | 3.500 | 2.438 | 17.50 | 3.720 | 0.1200 |
| Announcement Date | 3/27/18 | 3/26/19 | 3/16/20 | 3/10/21 | 3/1/22 | 3/30/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | 0.312 | 3.595 | 2.514 |
| EBITDA 1 | -18.98 | -11.31 | -8.925 | - | - | - |
| EBIT 1 | -19.03 | -11.33 | -8.944 | -88.2 | -232.8 | -68.3 |
| Operating Margin | - | - | - | -28,268.59% | -6,474.88% | -2,716.95% |
| Earnings before Tax (EBT) 1 | -21.99 | -12 | -10.29 | -89.54 | -236.6 | -70.73 |
| Net income 1 | -21.99 | -12 | -10.29 | -89.54 | -236.6 | -70.73 |
| Net margin | - | - | - | -28,697.12% | -6,582.73% | -2,813.44% |
| EPS 2 | -7.341 | -0.6334 | -0.4603 | -2.422 | -4.043 | -0.7926 |
| Free Cash Flow 1 | -8.97 | -2.941 | -1.643 | -41.59 | -93.7 | -51.23 |
| FCF margin | - | - | - | -13,331.33% | -2,606.38% | -2,037.78% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/27/18 | 3/26/19 | 3/16/20 | 3/10/21 | 3/1/22 | 3/30/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 Q4 | 2021 Q1 | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.312 | 0.486 | 1.036 | 1.036 | 1.037 | 1.036 | 1.036 | 0.221 | 0.221 | 0.221 |
| EBITDA | -32.3 | -64.4 | -70.05 | -65.98 | -32.34 | -20.53 | -29.35 | -22.72 | 4.297 | - |
| EBIT 1 | -32.3 | -64.4 | -70.05 | -65.98 | -32.34 | -20.53 | -29.35 | -22.72 | 4.297 | -4.235 |
| Operating Margin | -10,350.96% | -13,250.21% | -6,761.78% | -6,368.63% | -3,119.09% | -1,981.56% | -2,833.11% | -10,281% | 1,944.34% | -1,916.29% |
| Earnings before Tax (EBT) 1 | -32.3 | -65.57 | -70.8 | -66.74 | -33.54 | -21.28 | -30.15 | -23.69 | 4.39 | -4.182 |
| Net income 1 | -32.3 | -65.57 | -70.8 | -66.74 | -33.54 | -21.28 | -30.15 | -23.69 | 4.39 | -4.182 |
| Net margin | -10,350.96% | -13,491.15% | -6,834.27% | -6,441.99% | -3,234.33% | -2,053.86% | -2,910.14% | -10,720.81% | 1,986.43% | -1,892.31% |
| EPS 2 | -0.6300 | -1.250 | -1.200 | -1.120 | -0.5300 | -0.3200 | -0.4300 | -0.2300 | 0.1600 | -0.0400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/10/21 | 5/13/21 | 8/12/21 | 11/12/21 | 2/28/22 | 5/5/22 | 8/12/22 | 11/14/22 | 3/30/23 | 5/15/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 18.6 | 2.68 | 6.34 | - | - | - |
| Net Cash position 1 | - | - | - | 67.7 | 45 | 10.2 |
| Leverage (Debt/EBITDA) | -0.9815 x | -0.237 x | -0.7108 x | - | - | - |
| Free Cash Flow 1 | -8.97 | -2.94 | -1.64 | -41.6 | -93.7 | -51.2 |
| ROE (net income / shareholders' equity) | 153% | 74% | 91.8% | -573% | -2,165% | 201% |
| ROA (Net income/ Total Assets) | -372% | -466% | -591% | -160% | -209% | -104% |
| Assets 1 | 5.904 | 2.576 | 1.743 | 55.89 | 113.3 | 68.14 |
| Book Value Per Share 2 | -8.140 | -0.3700 | -0.6300 | 0.8800 | -0.3700 | -0.3900 |
| Cash Flow per Share 2 | 0.2500 | 0.0400 | 0.0100 | 1.310 | 1.090 | 0.0900 |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 3/27/18 | 3/26/19 | 3/16/20 | 3/10/21 | 3/1/22 | 3/30/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -83.33% | 23.82K | |
| -3.58% | 87.17B | |
| +1.97% | 40.1B | |
| +56.59% | 25.12B | |
| -14.82% | 15.59B | |
| -8.82% | 12B | |
| -16.29% | 11.8B | |
| -41.58% | 11.8B | |
| +6.14% | 8.81B | |
| -9.59% | 8.24B |
- Stock Market
- Equities
- HGENQ Stock
- Financials Humanigen, Inc.
